1. Home
  2. MPLT vs VMET Comparison

MPLT vs VMET Comparison

Compare MPLT & VMET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MapLight Therapeutics Inc.

MPLT

MapLight Therapeutics Inc.

BUY

Current Price

$37.09

Market Cap

1.3B

Sector

Health Care

ML Signal

BUY

VMET

Versamet Royalties Corporation Common Stock

N/A

Current Price

$11.82

Market Cap

1.3B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
MPLT
VMET
Founded
2018
2011
Country
United States
Canada
Employees
133
8
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.3B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
MPLT
VMET
Price
$37.09
$11.82
Analyst Decision
Strong Buy
Analyst Count
7
0
Target Price
$32.67
N/A
AVG Volume (30 Days)
437.1K
183.8K
Earning Date
05-28-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
$185.47
Revenue Next Year
N/A
$16.05
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$12.24
$9.10
52 Week High
$37.61
$13.81

Technical Indicators

Market Signals
Indicator
MPLT
VMET
Relative Strength Index (RSI) 69.84 47.55
Support Level $26.20 $10.83
Resistance Level N/A $13.64
Average True Range (ATR) 2.49 0.74
MACD 0.84 0.01
Stochastic Oscillator 95.22 32.98

Price Performance

Historical Comparison
MPLT
VMET

About MPLT MapLight Therapeutics Inc.

MapLight Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing treatments for central nervous system disorders. Its discovery platform identifies neural circuits causally linked to disease and targets them for therapeutic modulation, aiming to improve efficacy, safety, tolerability, and ease of use. The company was founded by leaders in psychiatry and neuroscience research to address the lack of circuit-specific pharmacotherapies. Its product candidate, ML-007C-MA, is a fixed-dose combination of an M1/M4 muscarinic agonist and a peripherally acting anticholinergic, being developed for schizophrenia and Alzheimer's disease psychosis, designed to activate central receptors while mitigating peripheral side effects.

About VMET Versamet Royalties Corporation Common Stock

Versamet Royalties Corp is a diversified metals royalty and streaming company with exposure to a range of resource royalties and streams including gold, silver, copper, zinc, graphite and uranium, across a variety of jurisdictions. The Company's operating segments are considered to be its individual royalties, streams and the Greenstone gold interest.

Share on Social Networks: